References
- Playford EG, Webster AC, Sorrell TC, Craig JC. Antifun-gal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006; 57 (4): 628–38.
- Castagnola E, Macbeth M, Bucci B, Viscoli C. Antifungal prophylaxis with azole dervatives. Clin Microbiol Infect, 2004; 10 (Supp1.1): 86-95.
- Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in pa-tients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91 (8): 1068–1075.
- Tortorano AM, Kibbler C, Pemanc J, Bernhardt H, Klingspor L, Grillot L. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrobial Agents 2006; 27 (5): 359–366.
- Clinical Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, vol. M27-A2:. CLSI, Wayne, Pa.
- Maxwell MJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Diekema DJ, et al. Evaluation of Etest method for determin-ing fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Mi-crobiol. 2003; 41 (3): 1087–90.
- MedCalc for Windows, Statistics for Biomedical Research, Software Manual. Version 8.1. Mariakerke, Belgium: MedCalc Software
- Nawrot U, Nowicka J, Juszczak K, Gusin B. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases. Mycoses 2005, 48 (6), 385–390.
- Cartledge JD, Midgley J, Gazzard BG. Clinically significant azole cross-resistance in Candida isolates from HIV-positive pa-tients with oral candidosis. AIDS. 1997; 11 (15): 1839–44.
- Candido RC, Toloi MR, Franceschini SA, Garcia FR, Minto EC. In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species. Mycopathologia. 1999; 144 (1): 15–20.
- Magill SS, Shields C, Sears CL, Choti M, Merz WG. Tr-azole cross-resistance among Candida spp.: case report, occur-rence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44 (2): 529-535.
- Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilu-tion Methods. J Clin Microbiol. 2007; 45 (1): 70–75.
- Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-re-sistance in Candida glabrata. J Clin Microbiol. 2006; 44 (5): 1740–3.
- Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol. 2004; 42 (7): 3137–41.